Market Newsdesk

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a partnership with leading research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions.

The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) at Indiana University. The project will generate large-scale plasma proteomic data from approximately 21,000 samples collected from 10,000 Alzheimer’s Disease Research Center (ADRC) participants across the United States. Samples are stored at NCRAD, providing a centralized national infrastructure for coordinated access and biomarker generation at scale.

Profiling will use Alamar Biosciences’ NULISAseq™ Neuro 220 panel, enhanced with a newly added eMTBR-Tau assay that enables simultaneous blood-based representation of tau tangle burden alongside a broad panel of neurodegeneration and neuroinflammation biomarkers. The panel also offers the largest number of brain-derived Tau targets along with assays relevant to alpha-synuclein biology and other protein aggregation markers, creating a unique opportunity to study multiple neurodegenerative disease pathways in the same deeply characterized participants.

“Our precision proteomics platform is designed to give researchers the ability to measure hundreds of low-abundance proteins from blood with attomolar sensitivity, at scale, and across highly multiplexed panels,” said Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. “Applying that capability to a cohort of this size will give researchers access to a deeply multiplexed, clinically anchored proteomic dataset that can support discovery, validation, and translational research across a range of neurodegenerative diseases. We see this as a major step toward understanding the full biological complexity of neurodegenerative disease.”

The project is part of the CLARiTI portfolio and leverages its infrastructure to support coordinated sample access and harmonized data workflows. The effort has been advanced through sustained partnerships with the Alzheimer’s Association, the Robertson Foundation, an anonymous foundation, and important implementation and data-sharing support from the Alzheimer’s Disease Data Initiative. All data generated through the initiative will be made freely available to the global research community.

A central goal is the creation of an open, publicly accessible proteomic dataset linked to National Alzheimer’s Coordinating Center (NACC) IDs. This linkage will allow researchers to connect the new proteomic profiles with rich longitudinal data available through the ADRC Program, including clinical, cognitive, neuroimaging, genetic, genomic, fluid biomarker, and neuropathology data. AI and computational teams will apply multimodal approaches for disease classification, biomarker discovery, and prediction of neurodegenerative disease progression. The next phase of the project will include a national data challenge inviting the broader research community to develop and test new analytical methods using this resource.

 “This effort is designed to move the field from single-disease models toward a more comprehensive understanding of the biological processes that contribute to mild cognitive impairment and dementia,” said Dr. Sterling Johnson. “Because ADRCs across the United States enroll and study diverse research participants, this multi-site cohort aligns well with the study’s scientific objectives. By generating an open, national-scale resource and engaging leading AI and computational teams, we also hope to accelerate discovery and create tools that ultimately improve diagnosis, treatment development, and patient care.”

About Alamar Biosciences

Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. 

Forward Looking Statements

This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ ability to unlock high-quality multiplexed proteomic data from remotely collected samples, the capabilities and performance of the NULISAseq™ Neuro 220 panel and the eMTBR-Tau assay, and the expected size, scope, and scientific output of the proteomics initiative. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Stellantis Reports Q2 2026 Estimated Consolidated Shipments of 1.6 Million Units, +10% Year-Over-Year

• North America Shipments Up 38%, Driven by New Product Launches; Enlarged Europe Also Reports Growth

AMSTERDAM, July 13, 2026 – Stellantis N.V. today released its Q2 2026 estimated consolidated shipments. The term “shipments” describes the volume of vehicles delivered to dealers, distributors, or directly from the Company to retail and fleet customers, which generally drive revenue recognition.

Consolidated shipments for the three months ended June 30, 2026, were an estimated 1.6 million units, up 10% year-over-year. Growth was driven primarily by North America and Enlarged Europe, partially offset by lower volumes in the Middle East & Africa, largely due to the regional conflict, and in South America, where a weaker Argentine market weighed on performance.

• In North America, Q2 shipments increased by approximately 122 thousand units, or 38% year-over-year. The majority of the growth was driven by new or refreshed products and powertrain offerings, including the Ram 1500 (light-duty) HEMI® V8, the new Ram 1500 TRX SRT, the refreshed Jeep_® Grand Wagoneer and Grand Cherokee, and the refreshed Chrysler Pacifica, in addition to the continued ramp-up of the all-new Jeep_® Cherokee and the all-new Dodge Charger 2-door and 4-door SIXPACK; it also reflects preparations for the planned summer production shutdown.
• In Enlarged Europe, Q2 shipments increased by approximately 39 thousand units, or 5% year-over-year, supported by higher industry volumes. Growth came from both Stellantis- and Leapmotor-branded vehicles, with BEV shipments serving as the primary driver. For Stellantis brands, shipment growth was driven primarily by recent product launches. Strong demand for Smart Car platform nameplates including the Citroën C3 and C3 Aircross, Opel/Vauxhall Frontera, and Fiat Grande Panda, contributed approximately 41 thousand additional units, representing 51% growth year-over-year. In the C-segment, the new Jeep_® Compass also contributed positively, adding approximately 8 thousand units. These gains were partially offset by an approximately 28-thousand unit decline in shipments of legacy B-SUV models, including Jeep Avenger, Fiat 600, Opel Mokka and Peugeot 2008. Leapmotor-branded vehicle shipments increased by approximately 25 thousand units to 33 thousand units, driven by strong demand for the T03 and the B10.
• In Middle East & Africa, shipments declined by approximately 4 thousand units, or 3% year-over-year, reflecting the impact of the regional conflict. Growth in the region was supported by Algeria, up approximately 8 thousand units, from the continued ramp-up of the Fiat Doblo and, to a lesser extent, higher shipments in Morocco driven by stronger industry volumes. These gains were more than offset by Türkiye, down approximately 8 thousand units, amid weaker market conditions, and shipments in Gulf Cooperation Council countries, which declined by approximately 50%.
• In South America, shipments declined by approximately 7 thousand units, or 3% year-over-year. The growth in Brazil, up approximately 21 thousand units, supported by favorable industry conditions, was more than offset by lower shipments in other markets, mainly in Argentina, where shipments declined by approximately 25 thousand units.
• Asia Pacific shipments remained flat year-over-year at 16 thousand units.

NOTES

⁽¹⁾  Consolidated shipments only include shipments by the Company’s consolidated subsidiaries, which represent new vehicles invoiced to third parties (dealers/importers or final customers). Consolidated shipment volumes for Q2 2026 presented here are unaudited and may be adjusted.

With effect from January 1, 2026, our Maserati reportable segment has been eliminated, and its shipments are reported consistently with our other brands, in that transactions are treated on a “where sold” basis. Comparative information has been restated.

Consolidated shipments include shipments for Leapmotor International, which is a jointly established, Stellantis-controlled company created in 2024 and owned 51 percent by Stellantis and 49 percent by Leapmotor, to distribute Leapmotor-branded vehicles outside of China.

# # #

About Stellantis

Stellantis (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep

_®

, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information,

www.stellantis.com

Safe Harbor Statement

This document, in particular references to “FY 2026 Financial Guidance”, contains forward looking

statements. In particular, statements regarding future financial performance and the Company’s

expectations as to the achievement of certain targeted metrics, including revenues, industrial free cash flows, vehicle shipments, capital investments, research and development costs and other expenses at any future date or for any future period are forward looking statements. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward looking statements are not guarantees of future performance. Rather, they are based on the Company’s current state of knowledge, future expectations and projections about future events and are by their nature, subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Actual results may differ materially from those expressed in forward looking statements as a result of a variety of factors, including: the Company’s ability to maintain vehicle shipment volumes; changes in the global financial markets, general economic environment and changes in demand for automotive products, which is subject to cyclicality; changes in trade policy, the imposition of global and regional tariffs targeted to the automotive industry; the Company’s ability to accurately predict the market demand for electrified vehicles; the Company’s ability to offer innovative, attractive products; a significant malfunction, disruption or security breach compromising information technology systems or the electronic control systems contained in the Company’s vehicles; the Company’s ability to attract and retain experienced management and employees; exchange rate fluctuations, interest rate changes, credit risk and other market risks; increases in costs, disruptions of supply or shortages of raw materials, parts, components and systems used in the Company’s vehicles; changes in local economic and political conditions; the enactment of tax reforms or other changes in tax laws and regulations; the level of governmental economic incentives available to support the adoption of battery electric vehicles; the impact of increasingly stringent regulations regarding fuel efficiency and greenhouse gas and tailpipe emissions; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims and environmental claims, investigations and lawsuits; material operating expenditures in relation to compliance with environmental, health and safety regulations; the level of competition in the automotive industry, which may increase due to consolidation and new entrants; exposure to shortfalls in the funding of the Company’s defined benefit pension plans; the Company’s ability to provide or arrange for access to adequate financing for dealers and retail customers; risks related to the operations of financial services companies; the Company’s ability to access funding to execute its business plan; the Company’s ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; risks associated with the Company’s relationships with employees, dealers and suppliers; the Company’s ability to maintain effective internal controls over financial reporting; developments in labor and industrial relations and developments in applicable labor laws; earthquakes or other disasters; and other risks and uncertainties.

Any forward-looking statements contained in this document speak only as of the date of this

document and the Company disclaims any obligation to update or revise publicly forward looking

statements. Further information concerning the Company and its businesses, including factors that

could materially affect the Company’s financial results, is included in the Company’s reports and filings with the U.S. Securities and Exchange Commission and AFM.

Attachment

• EN-20260713-Stellantis-Q2-2026-Shipments-Estimates

HONOLULU, July 12, 2026 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its second quarter 2026 financial results on Friday, July 24, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time).

To access the call by phone, participants will need to click on the following registration link: https://register-conf.media-server.com/register/BIb8e318d9b8d24417b3d7d113fcf80dbc, register for the conference call, and then you will receive the dial-in number and a personalized PIN code. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call, including a slide presentation, will be available at the following link: www.fhb.com/earnings. The archive of the webcast will be available at the same location.

About First Hawaiian

First Hawaiian, Inc. (NASDAQ:FHB) is a bank holding company headquartered in Honolulu, Hawaii. Its principal subsidiary, First Hawaiian Bank, founded in 1858 under the name Bishop & Company, is Hawaii’s oldest and largest financial institution with branch locations throughout Hawaii, Guam and Saipan. The company offers a comprehensive suite of banking services to consumer and commercial customers including deposit products, loans, wealth management, insurance, trust, retirement planning, credit card and merchant processing services. Customers may also access their accounts through ATMs, online and mobile banking channels. For more information about First Hawaiian, Inc., visit www.fhb.com.

Investor Relations Contact:
Kevin Haseyama
(808) 525-6268
[email protected]

Media Contact:

Bill Weeshoff
(808) 525-6229
[email protected]

SAN DIEGO, July 12, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, all dates inclusive (the “Class Period”), have until Monday, August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit. Captioned Basma v. GeneDx Holdings Corp., No. 26-cv-00880 (D. Conn.), the GeneDx class action lawsuit charges GeneDx as well as certain of GeneDx’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

GeneDx

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-genedx-holdings-corp-class-action-lawsuit-wgs.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert

of Robbins Geller by calling 800/851-7783 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: GeneDx is a genomics company that provides genetic testing services. On April 16, 2025, GeneDx announced an agreement to acquire Fabric Genomics. Fabric Genomics is a firm focused on AI-driven genomic interpretation.

The GeneDx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose significant problems in Fabric Genomic’s viability that would negatively impact GeneDx’s overall business and operations.

On May 4, 2026, GeneDx announced its 2026 first quarter results, allegedly revealing a drop in adjusted gross margin from 74% to 69%, reduced projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss directly attributable to Fabric Genomics. On this news, the price of GeneDx stock dropped over 49%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased GeneDx common stock during the Class Period to seek appointment as lead plaintiff in the GeneDx class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the GeneDx class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the GeneDx class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the GeneDx class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800/851-7783
        [email protected]

• The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1
• EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens
• Data presented today in poster presentation at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada

COPENHAGEN, Denmark, July 12, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

Data is presented today in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada.

EVX-V1 is a next-generation, multi-component CMV vaccine program designed with AI-Immunology™. It combines novel protective B-cell antigens and T-cell epitopes complemented by known optimized structural B-cell antigens

This broader multi-targeted strategy is expected to strengthen the protective potential of a future vaccine. The concept represents a scalable strategy for rational vaccine development across other herpesviruses.

“We are excited by the new data which will guide the selection of antigens for a broadly protective CMV vaccine candidate and as such represent an important step forward for the EVX-V1 program. CMV remains a major clinical challenge, causing severe disease in immunocompromised individuals and infants, yet no licensed vaccine exists. EVX-V1 holds the potential to transform the future CMV treatment landscape,” says Birgitte Rønø, CSO and COO of Evaxion.

The new data show that the AI-Immunology™ discovered novel T-cell epitopes have the potential to improve control of acute infection, latency and reactivation in CMV-infected mice. This complements previous findings of the novel B-cell antigens significantly reducing viral infection in preclinical models and the optimized known structural B-cell antigens mediating superior viral neutralization.

About EVX-V1

EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. Through this combination, EVX-V1 attacks the virus from multiple, complementary angles. This broader multi-targeted strategy is expected to strengthen the protective potential of the vaccine.

With our AI-Immunology™ platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field. These previously unexplored CMV-antigens induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal viral infection models.

EVX-V1 is a combination of these antigens with our proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen which has demonstrated superior performance compared to the traditional gB antigen, including enhanced CMV neutralization.

About CMV

About 1 in 200 babies is born with congenital CMV infection. About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems. CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, driving demand for CMV treatment. Despite decades of research, no CMV vaccine has been approved to date.

CMV treatment market size was valued at $474.6 million in 2023 and is anticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032. This growth is propelled by increasing awareness and prevalence of CMV infection and the development of new and effective treatments.

CMV is the most complex of all herpes viruses and is a widespread infection transmitted in body fluids. Once infected, the virus stays for life. People with weakened immune systems, including organ transplant patients, can develop severe symptoms affecting, for example, eyes, lungs, and liver, and congenitally infected babies may suffer from intellectual disability and loss of vision and hearing.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
[email protected]

About Evaxion

Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing

HMB-003 program announced as non-hormonal direct plasmin inhibitor with potent, selective and extended antifibrinolytic activity, designed to reduce bleeding across multiple settings beginning in heavy menstrual bleeding

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented new clinical data from HMB-002 in Von Willebrand disease (VWD) and announced the HMB-003 program at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France.

“Millions of people living with bleeding disorders including VWD and heavy menstrual bleeding have no reliable way to prevent excessive bleeds,” said Benny Sørensen, MD, PhD, CEO of Hemab. “Today, at ISTH 2026 we presented new HMB-002 data demonstrating proof of mechanism in VWD alongside preliminary clinical observations on treated bleeding events. We also unveiled HMB-003, a novel antifibrinolytic built on validated fatty-acid conjugated peptide technology, initially targeting heavy menstrual bleeding – an often-ignored vital sign. It affects one in three women, causing pain, iron-deficiency anemia, fatigue, stigma, and extensive lost days at school and work, with treatment options largely unchanged in decades. HMB-003 is non-hormonal, potent, and selective, engineered to cover the period, then wash out between cycles.”

“The new HMB-002 data support a non-replacement approach in VWD: a single subcutaneous dose raising both VWF and FVIII more than 2-fold, with a favorable safety profile across every cohort,” said Priyanka Raheja, MD, Consultant Haematologist at Barts Health NHS Trust. “Building on 50 years of clinically validated treatment strategy, HMB-002 shows potential to change the VWD treatment paradigm by addressing the root cause of the disease; a durable increase, and for many patients potential normalization, of both VWF and FVIII.”

Program Presentations

HMB-002 is designed to address the underlying biological drivers of VWD through a non-replacement approach—elevating the body’s endogenous levels of VWF and FVIII rather than infusing exogenous factor—with early first-in-human data building a compelling case for this paradigm shift.

• Extended half-life supporting infrequent dosing: Pharmacokinetic (PK) analysis confirmed dose-dependent increase in Cmax with prolonged duration.
• Dual VWF and FVIII elevation: In all dose cohorts tested, VWF and FVIII were elevated in a dose-dependent manner. In cohort A3 (150 mg), ≥2.4-fold elevation in both VWF and FVIII was achieved and accompanied by restoration of thrombin generation, shortening of APTT, and stable multimer distribution. The pharmacokinetic/pharmacodynamic (PK/PD) profile supports potential for monthly dosing.
• Emerging safety profile: Most treatment-emergent adverse events (TEAEs) were mild to moderate in severity, no serious TEAEs occurred, no events were considered related to HMB-002, and no participant discontinued the study due to TEAEs. There were no thromboembolic events, no injection site reactions, no thrombocytopenia, and no hypersensitivity reactions.
• Preliminary clinical observations: The single ascending dose (SAD) part of the study wasn’t designed to measure efficacy, so clinical observations should be considered descriptive in nature. Across the SAD cohorts, 8 of 9 evaluable patients had zero treated bleeds in the 28 days following HMB-002 dosing, with a mean ATBR of 1.6. Among participants treated with HMB-002, the baseline mean ATBR before HMB-002 treatment was 20.1 reflecting significant disease burden in Type 1 VWD, based on bleed data collected up to 5.5 months.

HMB-003 is a novel fatty-acid-conjugated peptide antifibrinolytic, designed to stabilize clots and reduce bleeding across multiple settings, beginning in heavy menstrual bleeding, with preclinical data supporting potent, selective antifibrinolytic activity and extended duration of action.

• Potent and selective plasmin inhibition: HMB-003 directly inhibits plasmin at its active site and inhibits fibrinolysis across both tPA- and uPA-driven pathways, while showing no effect on thrombin generation, platelet function, or coagulation in nonclinical studies.
• Extended antifibrinolytic activity: Following a single subcutaneous dose in minipigs, HMB-003 achieved peak plasma levels within hours and sustained antifibrinolytic activity for approximately one week, supporting the potential for cycle-matched dosing in heavy menstrual bleeding.

About Von Willebrand Disease

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying biology of the disease.‍

About HMB-002

HMB-002 is a monovalent human antibody being developed as the first-in-class subcutaneous prophylactic treatment for Von Willebrand Disease targeting the underlying cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852).

HMB-003

HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with a durable half-life — a proven therapeutic target in coagulation medicine — being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site, HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. HMB-003 is optimized to provide sustained bleed protection across multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an anti-fibrinolytic targeting plasmin inhibition in preclinical development for multiple high-unmet-need conditions, ranging from heavy menstrual bleeding, hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, the anticipated timelines for reporting data from Hemab’s clinical trials, the anticipated timelines for initiating a Phase 3 clinical trial of sutacimig and first-in-human studies of HMB-003, the clinical potential of sutacimig, HMB-002 and HMB-003, Hemab’s plans to expand its pipeline, and the sufficiency of Hemab’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:

Deerfield Group
Peg Rusconi
[email protected]    

Investors:

Hemab Therapeutics
Mads Behrndt
[email protected]

PASCAGOULA, Miss., July 11, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened the future USS George M. Neal (DDG 131), the fourth Flight III Arleigh Burke-class destroyer to be built at the company’s Ingalls Shipbuilding division.

The ship is named for Aviation Machinist’s Mate Third Class George M. Neal, a Korean War veteran and Navy Cross recipient. In 1951, Neal’s helicopter crashed during a rescue attempt in the North Korean mountains. He evaded enemy forces for nine days before being captured and held as a prisoner of war for two and a half years. He was released and returned to the United States in 1952 along with more than 320 fellow prisoners of war.

Performing the duties of the under secretary of the Navy, William Toti delivered the keynote address. “The future USS George M. Neal honors a legacy of extraordinary courage and sacrifice,” Toti said. “As we christen this ship, we mark another step toward building the Navy our nation needs. Flight III destroyers are critical to our nation’s security, and we are proud to accept each one built by the skilled workforce at Ingalls.”

Photos accompanying this release are available at: http://hii.com/news/hii-christens-guided-missile-destroyer-george-m-neal-ddg-131/.

Toti’s remarks highlighted the deep connection between the Navy’s mission and the dedicated Americans who design and build the ships that carry it forward. Building on that message, HII President and CEO Chris Kastner underscored the unique skill and commitment of the Ingalls Shipbuilding team.

“As a company, HII does a lot of amazing things, but only people — human beings — build ships. They build ships with their hands, their minds and toughness. The people of Ingalls Shipbuilding are among the finest craftsmen and craftswomen on the face of the Earth,” Kastner said. “When she is delivered, DDG 131 will be the most powerful surface combatant in the world. She will be ready. She’ll be ready because the United States of America makes a conscious choice, generation after generation for now 250 years, to invest in U.S. Navy ships, built by Americans, in America.”

The ship’s sponsor and daughter of the namesake, Kelley Neal Gray, performed the traditional bottle-breaking ceremony against the bow to formally christen DDG 131. In her remarks, she honored her father’s legacy and expressed gratitude to those who built the ship.

“On behalf of my family, I express my deepest gratitude to the United States Navy, to the incredible honor, for this magnificent destroyer after my father, George Milton Neal,” Gray said. “We are forever grateful that his life of service, sacrifice and courage will be remembered through a ship that will one day defend our nation and carry his legacy throughout the world.”

U.S. Rep. Mike Ezell, representing Mississippi’s 4th District, also addressed ceremony attendees.

“Today’s christening of the future USS George M. Neal is a proud moment for Mississippi and our nation,” Ezell said. “George M. Neal’s courage, sacrifice, and service represent the very best of America, and it is fitting that this warship will carry his legacy for generations to come. I’m grateful to the hardworking men and women of Ingalls Shipbuilding whose craftsmanship strengthens our Navy, supports our Gulf Coast economy, and helps keep our nation safe.”

To date, Ingalls has delivered 36 Arleigh Burke-class destroyers, including the first Flight III, USS Jack H. Lucas (DDG 125), and Ted Stevens (DDG 128). Flight III destroyers currently under construction include Jeremiah Denton (DDG 129), George M. Neal (DDG 131), Sam Nunn (DDG 133), Thad Cochran (DDG 135), and John F. Lehman (DDG 137). Ships in pre-planning include Telesforo Trinidad (DDG 139), Ernest E. Evans (DDG 141), Charles French (DDG 142), Richard J. Danzig (DDG 143), Intrepid (DDG 145), Robert Kerrey (DDG 146), and Ray Mabus (DDG 147).

Flight III Arleigh Burke-class destroyers represent the next generation of surface combatants and incorporate a number of design modifications that collectively provide significantly enhanced capability. Upgrades include the AN/SPY-6(V)1 Air and Missile Defense Radar (AMDR) and the Aegis Baseline 10 Combat System required to keep pace with the threats well into the 21st century.

Video of the ceremony, along with additional information on DDG 131 and the Arleigh Burke-class program, is available at www.hii.com/events/DDG131.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 44,000 strong. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:

Kimberly K. Aguillard
[email protected]
228-355-5663

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/173938d8-a6b0-484d-b1b9-dcf22b5e76f5